Research programme: antisense drug therapies - Ionis Pharmaceuticals/Janssen Biotech

Drug Profile

Research programme: antisense drug therapies - Ionis Pharmaceuticals/Janssen Biotech

Alternative Names: IONIS-JBI1-2.5Rx

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein synthesis inhibitors; RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 19 Jul 2016 IONIS JBI1 2.5Rx licensed to Janssen Biotech for the treatment of Gastro-intestinal autoimmune disorders
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 05 Jan 2015 Isis Pharmaceuticals and Janssen Biotech enter into a collaboration agreement to develop antisense drug therapies world-wide for Autoimmune disorders of the gastrointestinal tract
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top